Bicara grants new CCO option for 282,240 shares at $22.58 each

Bicara Therapeutics

Bicara Therapeutics

BCAX

0.00
  • Bicara Therapeutics granted Chief Commercial Officer Christopher Sarchi a non-qualified stock option for 282,240 shares, effective May 8, 2026.
  • Exercise price set at USD 22.58 per share, matching Nasdaq closing price on May 8.
  • Vesting set at 25% on first anniversary of start date, remaining shares in 12 equal quarterly installments, subject to continued service.
  • Award made under Bicara 2026 Inducement Plan, adopted by board in January 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130830PRIMZONEFULLFEED9718719) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.